Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
Date:11/1/2007

arget="_new">http://www.anadyspharma.com. A telephone replay will also be available approximately one hour after completion of the call. To access the telephone replay, dial 888-286-8010 (domestic) or 617-801-6888 (international), passcode 43320108. The webcast and telephone replay will be available through November 15, 2007.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. The Company is developing ANA598, a small-molecule, non- nucleoside inhibitor of the NS5B polymerase for the treatment of HCV and ANA773, an oral TLR7 agonist prodrug for cancer.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to the expected timing and planned development activities for ANA598 and ANA773, including the timing for initiating clinical trials, the belief that Anadys' investment in the ANA598 and ANA773 programs will create value for the company, the anticipated future clinical benefits of ANA598 and ANA773, Anadys' ability to achieve meaningful clinical milestones with existing cash reserves and the ability to modulate immunostimulatory responses to ANA773 by schedule of administration. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward- looking statements. For example, the results of preclinical studies may not be predictive of future results, and Anadys cannot provide any assurances that any of its product candidates will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. In addition, Anadys' results may be aff
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
4. Sonic Foundry reports GAAP loss as Q2 revenues rise
5. Fiserv reports $113.5 million in Q1 profit
6. Third Wave reports net loss of $18.9M for 2006
7. Musicnotes reports 45 percent growth in 2006
8. Sonic Foundry reports net loss, higher revenue
9. Sonic Foundry reports first cash-positive quarter
10. Merge Healthcare reports $10.8M net loss in Q3
11. Third Wave reports $5.2M third quarter loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... a meter in size, are around us every day. ... as in some innovative early cancer treatments, but they ... traffic emissions, cosmetics, sunscreen and electronics. , A team ... by Lan Yang, PhD, the Das Family Career Development ... collaborators at Tsinghua University in China have developed a ...
(Date:9/2/2014)... September 02, 2014 Press attending the ... to take advantage of the people and events in ... below are available throughout the day. Additionally, we will ... POET and DSM representatives as well as representatives from ... is appreciated. , Please remember to RSVP to ...
(Date:9/2/2014)... -- Technology Applications International Corporation (the "Company" or "NUUU")(OTC BB: ... Inc. has signed an additional exclusive licensing agreement with ... Johnson Space Center in Houston , ... Charles J. Scimeca , NUUU,s ... latest, exclusive agreement with NASA. In addition to our ...
(Date:9/2/2014)... Sept. 2, 2014 Orexigen Therapeutics, Inc. (Nasdaq: ... Patent and Trademark Office (PTO) has issued a patent ... for weight loss. NB32 is a fixed-dose combination of ... U.S. Patent No. 8,815,889 claims methods for treating insulin ... patent expires in 2024. If NB32 is approved for ...
Breaking Biology Technology:Engineers develop new sensor to detect tiny individual nanoparticles 2Engineers develop new sensor to detect tiny individual nanoparticles 3Press agenda for Project LIBERTY Grand Opening 2Press agenda for Project LIBERTY Grand Opening 3Press agenda for Project LIBERTY Grand Opening 4Press agenda for Project LIBERTY Grand Opening 5Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 2Technology Applications International Corporation Subsidiary Enters Into Additional Exclusive Agreement with NASA at a Signing Ceremony at the Johnson Space Center In Houston, Texas 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 2Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 3Orexigen Expands NB32 Intellectual Property Portfolio With New U.S. Patent 4
... AC Immune SA, a leader,in Alzheimer,s disease drug development, ... Immune as Technology Pioneer 2009 for its,accomplishments as an ... a deep impact on business and society. , ... that it has reached significant clinical,milestones in the development ...
... A 60-year-old,prostate cancer patient from Montpellier has become ... RapidArc(TM) technology from Varian Medical Systems,(NYSE: ... intensity modulated radiotherapy,(IMRT). Each of his treatments at ... city took just 75 seconds, several times faster ...
... Pharmaceuticals, Inc. (Nasdaq: PPHM ) today announced that it ... year 2009 on December 10, 2008 at 7:00 a.m. EST and ... at 11:30 a.m. EST on the same day. , ... results for the second quarter ended October 31, 2008 and will ...
Cached Biology Technology:Technology Pioneer 2009 - AC Immune Highlights Significant Clinical Milestones in Alzheimer's Disease Drug Development 2Prostate Cancer Patient in Montpellier Becomes First Cancer Patient in France Treated with Varian's RapidArc(TM) Radiotherapy 2Prostate Cancer Patient in Montpellier Becomes First Cancer Patient in France Treated with Varian's RapidArc(TM) Radiotherapy 3Peregrine Pharmaceuticals to Report Second Quarter FY 2009 Financial Results 2
(Date:9/2/2014)... New research suggests that professional baseball pitchers with poor ... days in a single season because of injury than are ... back and pelvis. , In the study, 347 pitchers were ... tilt in their pelvis as they raised a leg to ... miss at least 30 days cumulative, not consecutive ...
(Date:9/2/2014)... the University of Warwick in the UK and the ... Journal Early Human Development , has found that ... birth and the use of mechanical ventilation are key ... Mathematic abilities are crucial for lifelong academic attainment. Impairments ... Earlier studies of children who are born very preterm ...
(Date:9/2/2014)... the most ideal source of nutrition for infants ... in the evolution and civilizations of human beings. ... large number of bacterial species, including some opportunistic ... surprise to scientists and physicians. , Indeed, the ... the result of co-evolutionary and co-adaptive interactions between ...
Breaking Biology News(10 mins):In pro baseball pitchers, weak core linked to more missed days 2In pro baseball pitchers, weak core linked to more missed days 3Mechanical ventilation a key indicator for pre-term children's math problems 2Are human breast milk microbiome 'neutral'? 2Are human breast milk microbiome 'neutral'? 3
... on labor-intensive microscopic examination, using century-old cell-staining ... and may give false readings. , A ... Laboratories researcher Paul Gourley, has provided laboratory ... liver tumor cells at their earliest stages, ...
... Canadian Network for Vaccines and Immunotherapeutics, has announced,the ... well the thymus (an organ,located at the base ... a,functional abnormality of this organ in HIV-infected individuals. ... professor at,Université de Montréal, scientist at the CHUM ...
... used to synthesize plastic food containers has been ... of prostate cancer cell,potentially affecting the treatment efficacy ... published in the January 1 issue of Cancer,Research, ... to,exposure to the chemical BPA (bisophenol A), an ...
Cached Biology News:Novel ultrafast laser detection of cancer cells also may improve understanding of stem cells 2Novel ultrafast laser detection of cancer cells also may improve understanding of stem cells 3Estrogen-like Component of Plastic Stimulates Growth of Certain Prostate Cancer Cells 2
Our original highly-purified, robust Taq Polymerase which delivers consistently high yields and minimal background...
A formulation of our Biolase DNA Polymerase which contains a Red Loading Dye...
... Neogens enzyme-linked immunosorbent assay (ELISA) ... as screening devices for the detection of ... The kits are intended for forensic use ... samples be confirmed by a quantitative method ...
... SUPERaseIn RNase Inhibitor (patent pending) is ... that noncovalently binds and inhibits the most ... B, C, 1 and T1. SUPERaseIn can ... contamination could be problematic. It is ideal ...
Biology Products: